Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

• Status: Completed
• Trial end date: 2020-06-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate hypoxia due to the corona virus that causes COVID-19. Based on previous animal studies, the researchers hypothesize that the addition of an ARB is beneficial in abating acute lung injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sharp HealthCare
• Treatments: Angiotensin Receptor Antagonists; Losartan

Criteria

Inclusion Criteria:

• Confirmed COVID-19 positive test result

• Mild to moderate respiratory symptoms of COVID-19.

• Systolic blood pressure ≥ 105 mmHg.

• Screen within 3 days of a positive COVID-19 test.

• Age ≥18 years old.

• Access to a phone in the hospital room or an electronic device that is capable of receiving phone or video calls.

• Able to read/write/speak English or Spanish fluently.

• Subjects must have the capacity to provide consent or an appropriate LAR to provide informed consent.

• Negative pregnancy test for women of childbearing potential and subject is randomized to the study arm.

Exclusion Criteria:

• Severe allergy to any ARB or ACE-inhibitor, including angioedema

• In the intensive care unit at screening.

• Home meds include any kind of ACE inhibitor or ARB

• Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)

• Hyperkalemia >5.0 mmol/L at baseline or any time during treatment in the study treatment arm

• Creatinine Clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm